This paper is in the following e-collection/theme issue:

Scoping Review Protocols (Funded with Peer-Review-Reports) (7) Pharmacology and Pharmaceutics (52) Health Services Research (413) Clinical Cancer Research (73) Chemotherapy and Side Effects Management (52)

Published on in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/38167, first published .
Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review

Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review

Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review

Authors of this article:

Jonathan E Constance1 Author Orcid Image ;   Mary M McFarland2 Author Orcid Image ;   Tallie Casucci3 Author Orcid Image ;   Michael W Deininger4, 5 Author Orcid Image ;   Elena Y Enioutina1 Author Orcid Image ;   Kathleen Job1 Author Orcid Image ;   Richard S Lemons6 Author Orcid Image ;   Carol S Lim7 Author Orcid Image ;   Robert M Ward1 Author Orcid Image ;   Venkata Yellepeddi1 Author Orcid Image ;   Kevin M Watt1 Author Orcid Image
Article Authors Cited by (1) Tweetations (5) Metrics

Journals

  1. Guo H, Li Y, Lin J, Li D, Yang J, Wang J, Mao J, Wang Y, Yan X. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients. International Immunopharmacology 2024;129:111611 View